

Bart J A Rijnders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8781424/publications.pdf>

Version: 2024-02-01

81
papers

8,423
citations

126907

33
h-index

74163

75
g-index

85
all docs

85
docs citations

85
times ranked

11132
citing authors

#	ARTICLE	IF	CITATIONS
1	Significant Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Care in Hospitals Affecting the First Pillar of the HIV Care Continuum. <i>Clinical Infectious Diseases</i> , 2022, 74, 521-524.	5.8	12
2	Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cellâ€Depleted Patients. <i>Clinical Infectious Diseases</i> , 2022, 74, 1271-1274.	5.8	19
3	Interferon-Î±2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19. <i>Journal of Clinical Immunology</i> , 2022, 42, 232-239.	3.8	26
4	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2147331.	5.9	38
5	Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. <i>JAMA Network Open</i> , 2022, 5, e2147375.	5.9	30
6	Divergent SARS-CoV-2 Omicronâ€reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	11.9	337
7	Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. <i>Nature Communications</i> , 2022, 13, 915.	12.8	32
8	Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	9
9	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSAâ€FLU study. <i>Mycoses</i> , 2022, 65, 656-660.	4.0	3
10	Bacillus Calmette-GuÃ©rin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1278-1285.	6.0	37
11	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. <i>Nature Communications</i> , 2022, 13, 2583.	12.8	25
12	Incidence of HCV Reinfection Among HIV-Positive MSM and Its Association With Sexual Risk Behavior: A Longitudinal Analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, 460-467.	5.8	38
13	Frequency of Positive <i>Aspergillus</i> Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the Intensive Care Unit. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	18
14	Invasive Pulmonary Aspergillosis Goes Viral Again?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 275-277.	5.6	6
15	HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study. <i>Lancet HIV</i> , the, 2021, 8, e96-e105.	4.7	48
16	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3189.	12.8	139
17	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021, 47, 674-686.	8.2	49
18	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	8.2	106

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. <i>Journal of Infectious Diseases</i> , 2021, 223, 2020-2028.	4.0	28
20	<i>Aspergillus</i> in Critically Ill COVID-19 Patients: A Scoping Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 2469.	2.4	13
21	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. <i>Microorganisms</i> , 2021, 9, 1543.	3.6	23
22	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1234-1241.	3.0	14
23	Multinational Observational Cohort Study of COVID-19-associated Pulmonary Aspergillosis. <i>Emerging Infectious Diseases</i> , 2021, 27, 2892-2898.	4.3	82
24	Influenza-Associated Pulmonary Aspergillosis: Seek, and You Shall Find!. <i>Critical Care Medicine</i> , 2021, 49, e1265-e1266.	0.9	3
25	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 349-350.	5.8	20
26	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. <i>Medical Mycology</i> , 2020, 58, 444-452.	0.7	50
27	High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. <i>Mycoses</i> , 2020, 63, 122-130.	4.0	35
28	Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination?. <i>Clinical Infectious Diseases</i> , 2020, 71, 1764-1767.	5.8	37
29	<i>Madurella mycetomatis</i> , the main causative agent of eumycetoma, is highly susceptible to olorofim. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 936-941.	3.0	28
30	Persistent candida arthritis successfully treated with micafungin instillation and surgery. A case report. <i>Medical Mycology Case Reports</i> , 2020, 27, 29-31.	1.3	0
31	Point of care aspergillus testing in intensive care patients. <i>Critical Care</i> , 2020, 24, 642.	5.8	20
32	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003101.	8.4	18
33	Epidemiology of <i>Pneumocystis jirovecii</i> Pneumonia and (Non-)use of Prophylaxis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 224.	3.9	30
34	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
35	Paradoxical Trends in Azole-Resistant <i>Aspergillus fumigatus</i> in a National Multicenter Surveillance Program, the Netherlands, 2013-2018. <i>Emerging Infectious Diseases</i> , 2020, 26, 1447-1455.	4.3	46
36	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <i>Nature Communications</i> , 2020, 11, 3436.	12.8	321

#	ARTICLE	IF	CITATIONS
37	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP&EBMT, EORTC&IDG and SEIFEM survey. <i>Mycoses</i> , 2020, 63, 420-429.	4.0	7
38	Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. <i>Medical Mycology</i> , 2020, 58, 874-880.	0.7	8
39	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
40	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
41	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
42	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
43	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.9	28
44	Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. <i>PLoS ONE</i> , 2019, 14, e0210179.	2.5	32
45	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S244-S259.	5.8	40
46	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S260-S274.	5.8	73
47	Influenza and Invasive Aspergillosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2019, 69, 2037-2037.	5.8	4
48	Is HIV-1 viraemia below 20 copies/mL in antiretroviral-treated patients associated with virologic outcome?. <i>Infectious Diseases</i> , 2019, 51, 259-267.	2.8	6
49	Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy. <i>EClinicalMedicine</i> , 2019, 17, 100210.	7.1	19
50	Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives?. <i>Clinical Infectious Diseases</i> , 2019, 69, 1506-1508.	5.8	0
51	Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 269-277.	8.1	39
52	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	21
53	Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1463-1471.	5.8	189
54	Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving. <i>Journal of Virus Eradication</i> , 2019, 5, 179-190.	0.5	1

#	ARTICLE	IF	CITATIONS
55	High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virusâ€œCoinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands. <i>Clinical Infectious Diseases</i> , 2018, 66, 1352-1359.	5.8	59
56	The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors. <i>Journal of Infectious Diseases</i> , 2018, 218, 698-706.	4.0	40
57	The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azoleâ€œresistance. A nationwide survey and rationale for the <scp>DB</scp>â€œ<scp>MSG</scp> 002 study protocol. <i>Mycoses</i> , 2018, 61, 656-664.	4.0	26
58	HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. <i>Journal of Infectious Diseases</i> , 2018, 218, 688-697.	4.0	69
59	Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 471-480.	3.1	133
60	Acute hepatitis C in HIV-negative men who have sex with men in the Netherlands and Belgium: a call for action. <i>Sexually Transmitted Infections</i> , 2018, 94, 297-297.	1.9	4
61	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> ,the, 2018, 6, 782-792.	10.7	638
62	Reply to Darcis and Berkhout. <i>Journal of Infectious Diseases</i> , 2018, 218, 2020-2021.	4.0	0
63	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. <i>Lancet HIV</i> ,the, 2017, 4, e195-e204.	4.7	64
64	Influenza-associated Aspergillosis in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 524-527.	5.6	176
65	Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. <i>Lancet HIV</i> ,the, 2017, 4, e547-e554.	4.7	104
66	Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1423-1429.	9.1	89
67	Echinocandin to fluconazole stepâ€œdown therapy in critically ill patients with invasive, susceptible <i>Candida albicans</i> infections. <i>Mycoses</i> , 2016, 59, 179-185.	4.0	10
68	Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: TableÂ1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1632-1636.	3.0	24
69	Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. <i>Journal of Hepatology</i> , 2016, 64, 807-812.	3.7	26
70	Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy. <i>PLoS ONE</i> , 2016, 11, e0159243.	2.5	63
71	Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv115.	0.9	79
72	Evidence Gathered From Randomized Clinical Trials and Observational Studies on the Equivalence of Emtricitabine and Lamivudine. <i>Clinical Infectious Diseases</i> , 2015, 60, 1732-1733.	5.8	4

#	ARTICLE	IF	CITATIONS
73	Validation of a New Aspergillus Real-Time PCR Assay for Direct Detection of Aspergillus and Azole Resistance of Aspergillus fumigatus on Bronchoalveolar Lavage Fluid. Journal of Clinical Microbiology, 2015, 53, 868-874.	3.9	130
74	Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life. International Journal of Antimicrobial Agents, 2015, 46, 82-87.	2.5	23
75	Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles. Clinical Infectious Diseases, 2013, 57, 513-520.	5.8	308
76	Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerging Infectious Diseases, 2011, 17, 1846-1854.	4.3	381
77	Prevention of Catheter-Related Bacteremia with a Daily Ethanol Lock in Patients with Tunnelled Catheters: A Randomized, Placebo-Controlled Trial. PLoS ONE, 2010, 5, e10840.	2.5	429
78	Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 49, 1-45.	5.8	2,904
79	Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial. Pulmonary Pharmacology and Therapeutics, 2008, 21, 855-859.	2.6	32
80	Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia-Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study. Clinical Infectious Diseases, 2008, 47, 1507-1512.	5.8	92
81	Use of Semiautomatic Treatment Advice to Improve Compliance with Infectious Diseases Society of America Guidelines for Treatment of Intravascular Catheter-Related Infection: A Before-After Study. Clinical Infectious Diseases, 2003, 37, 980-983.	5.8	8